Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451555 | 0.89 | CSNK2A2 (0.55) | CSNK2A2CSNK2A1RAB9APTGER3NPC1 | |
| SCHEMBL6445400 | 0.89 | MAPK1 (0.45) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6446020 | 0.84 | KMT2A (0.48) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6445716 | 0.82 | GLB1 (0.49) | RAB9APTGER3MAPTPKMNPC1 | |
| SCHEMBL6447140 | 0.82 | PTGER3 (0.45) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6447053 | 0.81 | CSNK2A2 (0.49) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6445760 | 0.81 | CSNK2A2 (0.52) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6447131 | 0.81 | ABL1 (0.46) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6445925 | 0.81 | MAPT (0.53) | CSNK2A2CSNK2A1RAB9APTGER3MAPT | |
| SCHEMBL6447202 | 0.81 | KMT2A (0.46) | RAB9APTGER3MAPTNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | CSNK2A2 2523/4885CSNK2A1 1805/4885P4HTM 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.